Table 3. Characteristics of Ewing Sarcoma Survivors with Subsequent Malignant Neoplasms and Standardized Incidence Ratios (SIR).
| Characteristic | N (%) | SIR |
|---|---|---|
| Gender | ||
| Male | 12 (31.6) | 5.3 (2.7-9.2) |
| Female | 26 (68.4) | 9.8 (6.6-14.1) |
| Age at diagnosis of primary malignancy: Mean (Range) | 13.3 (4.2-20.5) | |
| Age at diagnosis of subsequent malignancy: Mean (Range)* | 30.5 (14.1-46.2) | |
| Interval between primary malignancy and subsequent malignancy* | ||
| 0-4 years | ||
| 5-9 years | 9 (22.0) | |
| 10-14 years | 7 (17.1) | |
| 15-19 years | 11 (26.8) | |
| ≥20 years | 14 (34.1) | |
| Subsequent Malignant Neoplasm** | ||
| Breast | 13 (31.7) | 14.9 (7.9-25.5) |
| Osteosarcoma | 9 (22.0) | 377.1 (172.1–715.9) |
| Other cancers | 7 (17.1) | 3.7 (1.5-7.6) |
| Thyroid | 6 (14.6) | 13.1 (4.8-28.5) |
| Melanoma | 1 (2.4) | 1.8 (0.0-9.8) |
| Acute Myeloid Leukemia | 2 (4.9) | 28.9 (3.2-104.2) |
| Lymphoid Leukemia | 1 (2.4) | 15.5 (0.2-86.3) |
| Soft Tissue Sarcomas | 1 (2.4) | 6.2 (0.7-22.3) |
| Alkylating agents | ||
| Yes | 33 (94.3) | 7.6 (5.3-10.6) |
| No | 2 (5.7) | 17.8 (3.6-52.0) |
| Anthracyclines | ||
| Yes | 28 (80.0) | 7.9 (5.3-11.3) |
| No | 7 (20.0) | 8.3 (3.8-15.7) |
| Topoisomerase II inhibitors | ||
| Yes | 1 (2.9) | 12.4 (0.2-68.8) |
| No | 34 (97.1) | 7.8 (5.5-10.8) |
| Radiation | ||
| Yes | 31 (88.6) | 8.6 (5.9-12.0) |
| No | 4 (11.4) | 4.2 (1.1-10.8) |
*
3 patients with 2 SMNs contributed two records in these calculations.
**
total adds to 41 since it includes 3 patients with two different SMN